ReShape Lifesciences Inc. Requests Nasdaq Hearing to Stay Delisting Despite Meeting Equity Requirement

Reuters06-19
ReShape Lifesciences Inc. Requests Nasdaq Hearing to Stay Delisting Despite Meeting Equity Requirement

ReShape Lifesciences Inc. has been notified by Nasdaq that its securities are subject to delisting due to not meeting the required minimum stockholders' equity. As of March 31, 2025, the company's stockholders' equity was $1.2 million. However, between June 3 and June 9, 2025, ReShape Lifesciences sold additional shares, raising its stockholders' equity above the required threshold. The company has requested a hearing before a Nasdaq Hearings Panel, which will delay any delisting action until a decision is made following the hearing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-060706), on June 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment